Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Sep 30;12(9):2425-2428.
doi: 10.21037/tcr-23-672. Epub 2023 Aug 11.

Severe COVID-19 outcomes and hematological cancers: the clot thickens-are platelets the culprit?

Lenard M Lichtenberger  1 , K Vinod Vijayan  2
Affiliations
Editorial

Severe COVID-19 outcomes and hematological cancers: the clot thickens-are platelets the culprit?

Lenard M Lichtenberger et al. Transl Cancer Res. .
No abstract available

Keywords: Hematological cancer; anti-CD20 therapy; breakthrough infections; platelets; rituximab.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-672/coif).The content of this article does not represent the views of the Department of Veterans Affairs or the US Government. LML reports that he receives a grant from National Institutes of Health (NIH) (No. R42 CA171408). LML is a co-founder of and shareholder in PLx Pharma Inc that is developing a phosphatidylcholine-associated aspirin for cardiovascular indications and he receives royalties from PLx Pharma Inc for sales of an aspirin product, Vazalore that was developed at the University of Texas Health Science Center at Houston and Licensed to PLx Pharma Inc. Vazalore is not used in the treatment or prevention of COVID-19. KVV reports that he receives a grant from National Institutes of Health (NIH) (No. R01 CA247917). The authors have no other conflicts of interest to declare.

Comment on

References

    1. Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 2020;136:2881-92. 10.1182/blood.2020008824 - DOI - PMC - PubMed
    1. Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov 2020;10:783-91. 10.1158/2159-8290.CD-20-0422 - DOI - PMC - PubMed
    1. Meggiolaro A, Sane Schepisi M, Nikolaidis GF, et al. Effectiveness of Vaccination against SARS-CoV-2 Infection in the Pre-Delta Era: A Systematic Review and Meta-Analysis. Vaccines (Basel) 2022;10:157. 10.3390/vaccines10020157 - DOI - PMC - PubMed
    1. Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39:1081-1090.e2. 10.1016/j.ccell.2021.06.002 - DOI - PMC - PubMed
    1. Wang L, Wang W, Xu R, et al. SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care. Best Pract Res Clin Haematol 2022;35:101384. 10.1016/j.beha.2022.101384 - DOI - PMC - PubMed